Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)HKSE:02500 -8.53%52 Net Debt Paydown Yield % is 35.13% as of Aug. 19, 2026, which is 17465% above its 10-year median of 0.20. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.34 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 768 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 97.53% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % was 35.13%.
Venus Medtech (Hangzhou) (HKSE:02500) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Venus Medtech (Hangzhou) Net Debt Paydown Yield % Related Terms
Venus Medtech (Hangzhou) Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) Net Debt Paydown Yield % Chart
HKSE:02500 vs ABT, SYK, MDT: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 35.13% mean?
Venus Medtech (Hangzhou) (HKSE:02500) has a Net Debt Paydown Yield % of 35.13% as of Aug. 19, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Venus Medtech (Hangzhou) and its competitors. This is 17465% above median its historical median of 0.20. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #19 out of 768 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % too high?
Venus Medtech (Hangzhou)'s current Net Debt Paydown Yield % of 35.13% is 17465% above median its 10-year median of 0.20. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. Venus Medtech (Hangzhou)'s value of 35.13% is 351200% above this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #19 out of 768 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Net Debt Paydown Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #19 out of 768 companies for Net Debt Paydown Yield %. This places Venus Medtech (Hangzhou) in the top 3% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.01. Venus Medtech (Hangzhou)'s value of 35.13% is 351200% above this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 0.01, Venus Medtech (Hangzhou) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Net Debt Paydown Yield % of 35.13% is 351200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Net Debt Paydown Yield % is 35.13%, which is 17465% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.34, compared to a current price of HK$0.97 — trading 71.1% below its estimated fair value. The current Net Debt Paydown Yield % is 35.13%, which is 17465% above median its 10-year median of 0.20 and 351200% above the Medical Devices & Instruments industry median of 0.01. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Net Debt Paydown Yield % is 35.13% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$0.97 is trading 71.1% below its estimated GF Value™ of HK$3.34.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Net Debt Paydown Yield %: 35.13% (17465% above median its 10-year median of 0.20)
GF Value™: HK$3.34 vs. price of HK$0.97 (71.1% below fair value)
Industry Position: 351200% above the Medical Devices & Instruments median (#19 of 768)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
